Methods and systems for analyzing and utilizing cancer testis antigen load

Characterizing cancer testis antigen burden through RNA-seq analysis of CTA gene markers predicts patient response to immune checkpoint inhibitors, enhancing treatment efficacy and cost-effectiveness.

JP2024541350AInactive Publication Date: 2024-11-08OMNISEQ INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024527746
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-11
Filing Date
2022-11-14
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is an unmet need for biomarkers that can better predict patient response to immune checkpoint inhibitor (ICI) therapy, which is costly and currently lacks effective predictive tools.

Method used

Characterizing cancer testis antigen burden (CTAB) using targeted RNA-seq approaches to measure the expression of a panel of cancer testis antigen (CTA) gene markers, enabling prediction of tumor response to immune checkpoint blockade therapy.

Benefits of technology

CTAB serves as a predictive marker for therapeutic response to ICIs, improving treatment outcomes by identifying favorable and less favorable responses, thereby optimizing ICI therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541350000001_ABST
    Figure 2024541350000001_ABST
Patent Text Reader

Abstract

The present disclosure relates to methods and systems for characterizing cancer testis antigen burden ("CTAB"), predicting cancer survival outcomes using CTAB analysis, and recommending and / or treating cancer using CTAB analysis. In particular, embodiments are directed to measuring the expression of a panel of cancer testis antigen (CTA) gene markers in tumor-forming tissues, determining CTAB based on the measured expression of CTA gene markers, predicting tumor response to immune checkpoint blockade therapy based on the determined CTAB, where the determined CTAB is associated with a predicted favorable response of the tumor to immune checkpoint blockade therapy when CTAB is ≧171, determining immune checkpoint blockade therapy for the tumor based on the predicted response of the tumor to immune checkpoint blockade therapy, and administering the determined immune checkpoint blockade therapy to the patient.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure is generally directed to methods and systems for characterizing cancer-testis antigen burden ("CTAB"), predicting cancer survival outcomes using CTAB analysis, and recommending and / or treating cancer using CTAB analysis. [Background technology]

[0002] Cancer testis antigen (CTA) has a highly tissue-restricted expression under normal gene regulation, and is expressed almost exclusively in male germ cells. When normal gene regulation is disrupted, such as in malignant tumors, CTA can be expressed in a variety of somatic tissues. When expressed in cancer cells, CTA is highly immunogenic and has the ability to induce cancer-specific immune responses in a variety of malignant tumors. As a result, CTA has become a major target for natural T cell responses, immune cell-based therapy, immune checkpoint inhibitors (ICI) or immune checkpoint blockade (ICB), and cancer vaccines.

[0003] ICIs have emerged as effective treatments in a variety of cancers, including breast cancer, colorectal cancer, and lung cancers such as non-small cell lung cancer (NSCLC). NSCLC accounts for approximately 50% of brain metastases. Although the clinical utility of single-agent ICIs or in combination with chemotherapy is well established, ICI-based immunotherapy is estimated to cost between 100,00 and 250,000 USD per patient. As a result, there remains an unmet need for the development of biomarkers that can better predict patient response to ICI treatment. Summary of the Invention [Means for solving the problem]

[0004] This disclosure relates to a method for characterizing a patient's response to ICI treatment. Co-expression of multiple CTA genes occurs in many tumor types and can be reliably detected using a targeted RNA-seq approach. Utilizing this co-expression pattern to calculate cancer-testis antigen burden (CTAB) reveals tumor type signatures that are associated with overall survival (OS) in a small NSCLC cohort. These immunogenic antigens expose tumor cells to natural or immunotherapy-enhanced cell-based immune responses, and therefore CTAB is a predictive marker of therapeutic response to ICI.

[0005] In various embodiments, a method for characterizing a patient's tumor response to immune checkpoint blockade therapy is provided, the method comprising: (a) obtaining tissue from the tumor; (b) measuring expression of a panel of cancer testis antigen (CTA) gene markers in the tissue; (c) determining a cancer testis antigen burden (CTAB) based on the measured expression of the CTA gene markers; (d) predicting the tumor's response to immune checkpoint blockade therapy based on the determined CTAB, where the determined CTAB is associated with a predicted favorable response of the tumor to immune checkpoint blockade therapy when CTAB is ≧171; (e) determining an immune checkpoint blockade therapy for the tumor based on the predicted response of the tumor to immune checkpoint blockade therapy; and (f) administering the determined immune checkpoint blockade therapy to the patient.

[0006] In various embodiments, a diagnostic test is provided for characterizing the CTAB of a tumor using a panel of CTA genes. The diagnostic test includes the steps of: (a) obtaining tissue from the tumor; (b) measuring the expression of a panel of cancer testis antigen (CTA) gene markers in the tissue; (c) determining the CTAB based on the measured expression of the CTA gene markers; (d) characterizing the tumor as high CTAB when CTAB is ≧171 and as low CTAB when CTAB is <170; and (e) predicting a favorable response of the tumor to immune checkpoint blockade therapy when the tumor has high CTAB and a less favorable response of the tumor to immune checkpoint blockade therapy when the tumor has low CTAB.

[0007] In various embodiments, a method is provided that includes: (a) measuring expression of a panel of cancer testis antigen (CTA) gene markers in a tumor-forming tissue; (b) determining a cancer testis antigen burden (CTAB) based on the measured expression of the CTA gene markers; (c) predicting a response of the tumor to an immune checkpoint blockade therapy based on the determined CTAB, wherein the determined CTAB is associated with a predicted favorable response of the tumor to immune checkpoint blockade therapy when CTAB is > 171; and (d) determining an immune checkpoint blockade therapy for the tumor based on the predicted response of the tumor to immune checkpoint blockade therapy.

[0008] In some embodiments, expression of the CTA gene markers is measured by RNA-seq.

[0009] In some embodiments, the tumor is non-small cell lung cancer (NSCLC).

[0010] In some embodiments, the panel of CTA genetic markers includes XAGE1B, SSX2, MLANA, MAGEC2, MAGEA12, MAGEA10, MAGEA4, MAGEA3, MAGEA1, GAGE13, GAGE12J, GAGE10, GAGE2C, CTAG2, CTAG1B, and BAGE.

[0011] In some embodiments, the immune checkpoint blockade therapy comprises one or more of nivolumab, pembrolizumab, ipilimumab, atezolizumab, and durvalumab.

[0012] In some embodiments, a system is provided that includes one or more data processors and a non-transitory computer-readable medium storing instructions that, when executed on the one or more data processors, cause the one or more data processors to perform some or all of one or more methods or processes disclosed herein.

[0013] In some embodiments, a computer program product is provided that is tangibly embodied in a non-transitory machine-readable medium and includes instructions configured to cause one or more data processors to perform some or all of one or more of the methods disclosed herein.

[0014] The terms and expressions employed are used as terms of description and not of limitation, and the use of such terms and expressions is not intended to exclude the features shown and described or equivalents of portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, although the present invention has been specifically disclosed by embodiments and optional features, it is to be understood that modifications and variations of the concepts disclosed herein may be employed by those skilled in the art, and such modifications and variations are deemed to be within the scope of the invention as defined by the appended claims.

[0015] The invention will be better understood in view of the following non-limiting drawings. [Brief description of the drawings]

[0016] [Figure 1] 1 shows representation of 5,450 samples from clinically tested FFPE tumors across 39 cancer types, according to various embodiments. [Diagram 2] 1 depicts a flowchart showing the calculation of gene expression normalized reads per million (nRPM) from raw absolute read count values ​​in a discovery cohort, according to various embodiments. [Diagram 3] 1 shows gene expression across all tumors for 17 CTAs classified as positive (nRPM≧20) or negative (nRPM<20) according to various embodiments. [Figure 4] 1 shows CTAB distribution in A) discovery, B) TCGA, and C) retrospective cohorts according to various embodiments. [Diagram 5] FIG. 1 shows cancer type CTAB distribution in A) discovery, B) TCGA, and C) retrospective cohorts according to various embodiments. [Figure 6] 1 shows CoxPH regression analysis of the effect of CTAB, age, and sex in A) TCGA and B) retrospective cohorts, according to various embodiments. [Figure 7] 1 shows Kaplan-Meier survival analysis comparing CTAB positive (≧171) and negative (<171) groups for A) TCGA and B) retrospective cohorts, according to various embodiments. [Figure 8] 1 shows the co-expression patterns of 15 cancer testis antigens across 5450 tumors of DC according to various embodiments. Pairwise Pearson correlation values ​​are shown in each grid square and colored according to the correlation value, as indicated by the shaded bar on the right. A black "X" through the square indicates a non-significant (p>0.05) correlation, and black squares around the chart diagonal indicate clusters of co-expressed CTAs. [Figure 9] 1 shows a violin plot detailing the distribution of cancer testis antigen burden (CTAB) in each of the 39 histologies represented in the 5450-sample DC, according to various embodiments. [Figure 10] PCA and hierarchical clustering results: A) Eigenvector plot detailing the influence of the five constituent biomarkers on the first two principal components, B) Classification of the 110 patient NSCLC validation cohort into four phenotypes, and C) Distribution of the four phenotypes within the validation cohort according to various embodiments. [Figure 11] Kaplan-Meier survival analysis of the NSCLC validation cohort (n=110) stratified by: A) PD-L1 IHC status, B) TMB status, C) cell proliferation, D) tumor immunogenic signature (TIGS), E) CTAB, and F) phenotype according to various embodiments. [Figure 12] 1 shows CoxPH survival analysis of phenotype, five component biomarkers, and sex and race as survival predictors, according to various embodiments. [Figure 13] 1 shows disease control rates (DCRs) of a validation cohort of 110 NSCLC patients subdivided into four phenotypes: tumor dominant, proliferative, inflammatory, and checkpoint, according to various embodiments. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0017] In the accompanying figures, similar components and / or features may have the same reference label. Furthermore, various components of the same type may be distinguished by following the reference label by a dash and a second label that distinguishes between the similar components. If only a first reference label is used in this specification, the specification is applicable to any one of the similar components having the same first reference label, regardless of the second reference label.

[0018] The following description provides only preferred exemplary embodiments and is not intended to limit the scope, applicability, or configuration of the present disclosure. Rather, the following description of preferred exemplary embodiments will provide those skilled in the art with an enabling description for implementing various embodiments. It should be understood that various changes may be made in the function and arrangement of elements without departing from the spirit and scope as set forth in the appended claims.

[0019] Specific details are set forth in the following description to provide a thorough understanding of the embodiments. However, it will be understood that the embodiments may be practiced without these specific details. For example, circuits, systems, networks, processes, and other components may be shown as block diagram components in order to avoid obscuring the embodiments in unnecessary detail. In other instances, well-known circuits, processes, algorithms, structures, and techniques may be shown without unnecessary detail in order to avoid obscuring the embodiments.

[0020] It should also be noted that the particular embodiments may be described as a process that is depicted as a flowchart, a flow diagram, a data flow diagram, a structure diagram, or a block diagram. Although a flowchart or diagram may describe operations as a sequential process, many operations may be performed in parallel or concurrently. Additionally, the order of operations may be rearranged. A process terminates when its operations are completed, but may have additional steps not included in the diagram. A process may correspond to a method, a function, a procedure, a subroutine, a subprogram, etc. When a process corresponds to a function, its termination may correspond to a return of the function to the calling function or to the main function.

[0021] Techniques for characterizing CTAB The present invention is directed to methods and systems for predicting ICI response and survival in patients with tumors across multiple histological types, particularly NSCLC.

[0022] In one embodiment, the pan-cancer discovery cohort (DC) was studied to develop cutoffs for low and high CTAB. Standard of care comprehensive genomic and immune profiling was performed on 5450 FFPE tumors representing 39 tissue types, assessing the expression levels of 395 immune genes and over 500 tumor-related genes. Sample inclusion criteria were based on clinical QC parameters for RNA-seq. As shown in Figure 1, DC mainly consisted of lung cancer (40.4%), followed by colorectal cancer (10.6%), breast cancer (8.64%), and ovarian cancer (4.73%), with lesser proportions of other cancer types. Targeted RNA-seq was performed on 5450 FFPE tumors. Three gene expression signatures were calculated from gene expression data of DC: cell proliferation (CP), tumor immunogenicity signature (TIGS), and cancer testis antigen burden (CTAB). The PD-L1 status of each tumor was assessed by IHC, and tumor mutational burden (TMB) was calculated.

[0023] In the second embodiment, a cohort from The Cancer Genome Atlas (TCGA) was used to validate the CTAB distribution-based classifier, which was a non-ICB-treated population. TCGA included 19923 tumors across 32 tumor types. In the third embodiment, the nearest neighbor method was then used to classify a retrospective validation cohort (RC) of 242 ICI-treated patients, including 110 NSCLC patients, as well as melanoma and renal cell carcinoma patients.

[0024] Using an amplicon-based NGS approach, the expression levels of 17 CTAs were ranked against a pan-cancer reference population. The method for calculating gene expression normalized reads from raw absolute read counts and calculating gene expression (GEX) rank is shown in Figure 2. As shown in Figure 3, the CTAs measured are XAGE1B, SSX2, MLANA, MAGEC2, MAGEA12, MAGEA10, MAGEA4, MAGEA3, MAGEA1, GAGE13, GAGE12J, GAGE10, GAGE2C, CTAG2, CTAG1B, and BAGE. The prevalence of positive CTA expression ranged from 3% (GAGE13) to 31.5% (XAGE1B) across the 5450 tumors studied. The co-expression patterns of 15 of the CTAs across the 5450 tumors in DC are shown in Figure 8. Co-expression of CTAs was observed across several histotypes, with the highest levels of co-expression observed within the MAGEA and GAGE ​​families.

[0025] CTAB was calculated for each sample, cohort, and tumor type as the sum of the 17 CTA gene expression ranks. The results for each cohort CTAB composition are shown in Table 1 below. As shown in Figure 4, each of the three cohorts demonstrated overlapping single-peaked left-leaning CTAB distribution curves centered around a CTAB value of 171 for DC ad 256 of RC. The DC median CTAB of 171 was used to classify all three cohorts into high and low CTAB groups. [Table 1]

[0026] As shown in Figures 5 and 9, when grouped by tumor type and ordered by median CTAB, the CTAB distribution of tumor types within the three cohorts was comparable. CTAB values ​​ranged from 0 to 1700, with renal cancer demonstrating the lowest mean CTAB overall (110) and melanoma the highest (550). The mean CTAB for NSCLC was 283.

[0027] As shown in Figure 6, OS analysis was performed for the TCGA and ICB-treated cohorts using CoxPH regression model to determine hazard ratios (HR). CoxPH regression analysis revealed an association between CTAB threshold classifier and OS in both ICB-treated RC and non-ICB-treated TCGA. However, the direction of this association differed between the two cohorts, with high CTAB samples having better survival in ICB-treated RC (HR=0.936, p=0.076) and worse survival in non-ICB-treated TCGA (HR: 1.007, p=0.084).

[0028] Kaplan-Meier survival analysis comparing CTAB-positive (≥171) and -negative (<171) groups in TCGA and RC Kaplan-Meier revealed a strong association (p<0.000) between CTAB positivity in TCGA and worse survival, as shown in Figure 7. This association was absent in RC (p=0.64), although there was a trend toward better survival with positive CTAB status. This difference suggests that advances in CTA-targeted immunotherapy have largely eliminated the survival disadvantage observed in TCGA prior to immunotherapy.

[0029] CTAB distribution was maintained across DC and TCGA, and across a broad range of tumor types, supporting CTAB as a valid, histology-agnostic classifier. Furthermore, when evaluating ICB-treated and non-ICB-treated cohorts, CTAB demonstrated the ability to predict OS, highlighting the utility of ICB in supporting CTA-specific innate immune responses.

[0030] DC was further evaluated by comprehensive genomic and immune profiling of the tumor immune microenvironment. Individual and combined biomarker assessment included PD-L1 IHC, TMB, tumor inflammation (TIGS), cellular proliferation (CP) and cancer testis antigen burden (CTAB). From DC, combinations of molecular and immune biomarkers were identified and applied to a subcohort of 110 metastatic NSCLC patients with RC treated with pembrolizumab + chemotherapy or pembrolizumab alone to correlate with response. Comparison of objective response rates (ORR) was performed using chi-square test. Kaplan-Meier analysis was performed to test for differences in OS and 1-year OS.

[0031] Example 1. In 110 samples of ICB-treated NSCLC patients from a 242-sample subcohort, high CTAB was associated with better OS compared to low CTAB (HR: 0.55, p=0.07). Furthermore, when combined with tumor inflammation and cell proliferation biomarkers, highly inflammatory but less proliferative tumors with high CTAB had improved OS (HR: 0.27, p=0.05). A significant association with higher response (HR=1.84, p=0.05) was detected for the entire 242-sample RC.

[0032] [Table 2]

[0033] As shown in Figure 10, analysis of DC revealed four distinct biomarker combination groups describing the underlying tumor immunobiology: tumor dominant (CTAB, TMB, CP high), proliferative (CP high), inflammatory (TIGS high), and checkpoint (PDL1, TIGS and TMB high). Application of these biomarker groups to RC demonstrated significant differences in responsiveness to ICI regimens between groups (p=0.04). Patients in the proliferative group (35.1%, 79 / 225, median PD-L1=20%TPS) treated with single-agent pembrolizumab showed a significantly higher ORR (59%, 16 / 27), significantly improved 1-year OS (p=0.03), and a trend toward better OS (p=0.14) compared to pembrolizumab + chemotherapy (27%, 14 / 52, p=0.005). Importantly, patients in the inflammatory group (16%, 36 / 225, median PD-L1=1% TPS) suggested that pembrolizumab plus chemotherapy (ORR 26.1%, 6 / 23) was not associated with ORR compared with pembrolizumab (ORR 31%, 4 / 13, p=0.76), or OS (p=0.37) and 1-year OS (p=0.57). Consequently, PD-L1 low NSCLC patients with a proliferative phenotype may benefit from single-agent pembrolizumab, while PD-L1 low cases with an inflammatory phenotype may benefit from both single-agent and combination pembrolizumab.

[0034] The association of these groups with ICI treatment efficacy was determined by overexpression analysis, and overall survival was assessed by Kaplan-Meier and CoxPH analysis, as shown in Figures 11 and 12. Kaplan-Meier survival analysis suggested a significant association between these groups and overall survival [p=0.035], demonstrating that the proliferation and checkpoint groups had a longer survival than the tumor-dominant and inflammation groups. Phenotypic stratification demonstrated a greater increase in median survival than any of the constituent biomarker stratifications. CoxPH analysis showed that the checkpoint group had a significantly reduced hazard ratio for ICI treatment [HR=0.10, p=0.038]. In all Kaplan-Meier and CoxPH analyses, the checkpoint group was a better predictor of survival than any of its constituent biomarkers.

[0035] Furthermore, a significant association with ICI response was found by classifying RC into four groups, namely, tumor-dominant [DCR=0.200], proliferative [DCR=0.273], inflammatory [DCR=0.154], and checkpoint [DCR=0.417], as shown in Figure 13. The checkpoint group had the highest rate of disease control [p=0.0313].

[0036] An integrated approach combining comprehensive tumor profiling with novel biomarkers better predicts ICI response and survival in multiple histological types. The divergent results between the resulting groups are likely a result of different tumor-immune interaction modes.

[0037] Additional Considerations Specific details are set forth in the above description to provide a thorough understanding of the embodiments. However, it will be understood that the embodiments may be practiced without these specific details. For example, circuits may be shown in block diagrams in order to avoid obscuring the embodiments in unnecessary detail. In other instances, well-known circuits, processes, algorithms, structures, and techniques may be shown without unnecessary detail in order to avoid obscuring the embodiments.

[0038] The implementation of the above techniques, blocks, steps, and means can be done in various ways. For example, these techniques, blocks, steps, and means can be implemented in hardware, software, or a combination thereof. In the case of hardware implementation, the processing unit can be implemented in one or more application specific integrated circuits (ASICs), digital signal processors (DSPs), digital signal processing devices (DSPDs), programmable logic devices (PLDs), field programmable gate arrays (FPGAs), processors, controllers, microcontrollers, microprocessors, other electronic units designed to perform the functions described above, and / or combinations thereof.

[0039] It is also noted that the embodiments may be described as a process that is depicted as a flowchart, a flow diagram, a data flow diagram, a structure diagram, or a block diagram. Although a flowchart may describe operations as a sequential process, many operations may be performed in parallel or concurrently. In addition, the order of operations may be rearranged. A process terminates when its operations are completed, but may have additional steps not included in the diagram. A process may correspond to a method, a function, a procedure, a subroutine, a subprogram, etc. When a process corresponds to a function, its termination corresponds to a return of the function to the calling function or the main function.

[0040] Further, embodiments may be implemented by hardware, software, scripting languages, firmware, middleware, microcode, hardware description languages, and / or any combination thereof. When implemented in software, firmware, middleware, scripting languages, and / or microcode, the program code or code segments to perform the necessary tasks may be stored in a machine-readable medium, such as a storage medium. A code segment or machine-executable instructions may represent a procedure, a function, a subprogram, a program, a routine, a subroutine, a module, a software package, a script, a class, or any combination of instructions, data structures, and / or program statements. A code segment may be coupled to another code segment or a hardware circuit by passing and / or receiving information, data, arguments, parameters, and / or memory contents. Information, arguments, parameters, data, etc. may be passed, forwarded, or transmitted via any suitable means including memory sharing, message passing, ticket passing, network transmission, etc.

[0041] In a firmware and / or software implementation, the methodologies may be implemented with modules (e.g., procedures, functions, and so on) that perform the functions described herein. Any machine-readable medium tangibly embodying instructions may be used in implementing the methodologies described herein. For example, software code may be stored in a memory. The memory may be implemented within the processor or external to the processor. As used herein, the term "memory" refers to any type of long-term, short-term, volatile, non-volatile, or other storage medium and is not limited to any particular type or number of memories or type of medium on which the memory is stored.

[0042] Additionally, as disclosed herein, the terms "storage medium," "storage," or "memory" may refer to one or more memories for storing data, including read-only memory (ROM), random access memory (RAM), magnetic RAM, core memory, magnetic disk storage media, optical storage media, flash memory devices, and / or other machine-readable media for storing information. The term "machine-readable medium" includes, but is not limited to, portable or fixed storage devices, optical storage devices, wireless channels, and / or various other storable media that can contain or carry instructions and / or data.

[0043] While the principles of the present disclosure have been described above in connection with specific apparatus and methods, it is to be clearly understood that this description is made only by way of example and not as a limitation on the scope of the disclosure.

Claims

1. 1. A method for characterizing a response of a patient's tumor to immune checkpoint blockade therapy, comprising: (a) obtaining tissue from the tumor; (b) measuring the expression of a panel of cancer testis antigen (CTA) genetic markers in said tissue; (c) determining the cancer-testis antigen burden (CTAB) based on the measured expression of the CTA genetic markers; (d) predicting the response of the tumor to immune checkpoint blockade therapy based on the determined CTAB, predicting, wherein the determined CTAB is associated with a predicted favorable response of the tumor to immune checkpoint blockade therapy when the CTAB is > 171; (e) determining an immune checkpoint blockade therapy for the tumor based on the predicted response of the tumor to immune checkpoint blockade therapy; (f) administering the determined immune checkpoint blockade therapy to the patient.

2. 1. A diagnostic test for characterizing the cancer testis antigen burden (CTAB) of a tumor using a panel of cancer testis antigen (CTA) genes, comprising: (a) obtaining tissue from the tumor; (b) measuring the expression of said panel of CTA genetic markers in said tissue; (c) determining the CTAB based on the measured expression of a CTA genetic marker; (d) characterizing the tumor as CTAB high when CTAB is > 171 and as CTAB low when CTAB is < 170; (e) predicting a favorable response of the tumor to immune checkpoint blockade therapy when the tumor has a high CTAB, and a less favorable response of the tumor to immune checkpoint blockade therapy when the tumor has a low CTAB.

3. The method of claim 1, wherein the expression of the CTA gene marker is measured by RNA-seq.

4. 2. The method of claim 1, wherein the tumor is non-small cell lung cancer (NSCLC).

5. The panel of CTA genetic markers comprises:

2. The method of claim 1, comprising XAGE1B, SSX2, MLANA, MAGEC2, MAGEA12, MAGEA10, MAGEA4, MAGEA3, MAGEA1, GAGE13, GAGE12J, GAGE10, GAGE2C, CTAG2, CTAG1B, and BAGE.

6. 2. The method of claim 1, wherein the immune checkpoint blockade therapy comprises one or more of nivolumab, pembrolizumab, ipilimumab, atezolizumab, and durvalumab.

7. 1. A system comprising: one or more data processors; and a non-transitory computer-readable medium storing instructions that, when executed on the one or more data processors, cause the one or more data processors to: (a) measuring the expression of a panel of cancer testis antigen (CTA) genetic markers in tumor-forming tissue; (b) determining a cancer-testis antigen burden (CTAB) based on the measured expression of the CTA gene marker; (c) predicting the tumor's response to immune checkpoint blockade therapy based on the determined CTAB, wherein the determined CTAB is associated with a predicted favorable response of the tumor to immune checkpoint blockade therapy when the CTAB is >= 171; and (d) determining an immune checkpoint blockade therapy for the tumor based on the predicted response of the tumor to immune checkpoint blockade therapy.

8. The system of claim 7, wherein the expression of the CTA gene marker is measured by RNA-seq.

9. The system of claim 7 , wherein the tumor is non-small cell lung cancer (NSCLC).

10. The panel of CTA genetic markers comprises:

8. The system of claim 7, including XAGE1B, SSX2, MLANA, MAGEC2, MAGEA12, MAGEA10, MAGEA4, MAGEA3, MAGEA1, GAGE13, GAGE12J, GAGE10, GAGE2C, CTAG2, CTAG1B, and BAGE.

11. 8. The system of claim 7, wherein the immune checkpoint blockade therapy comprises one or more of nivolumab, pembrolizumab, ipilimumab, atezolizumab, and durvalumab.

Citation Information

Patent Citations

  • Method for examining therapeutic effect on cancer and composition for inducing immune response

    WO2018207866A1